Anavex®2–73 (blarcamesine) phase 2b/3 study met primary and key secondary endpoints, showing statistically significant reduction of clinical decline in global clinical study of patients with early alzheimer's disease

New york, dec. 01, 2022 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced positive topline results from its phase 2b/3 anavex®2-73-ad-004 clinical trial of oral anavex®2-73 (blarcamesine) for the treatment of mild cognitive impairment (mci) due to alzheimer's disease (ad) and mild ad (collectively known as early ad). anavex®2-73 met the primary endpoints adas-cog1 and adcs-adl2 and key secondary endpoint cdr-sb3 with statistically significant results. next step, in light of this data, is meeting with regulatory authorities to discuss this data in the context of ongoing development with an aim to bring this therapy to patients in europe, asia-pacific, and the u.s.
AVXL Ratings Summary
AVXL Quant Ranking